Aprea Therapeutics (APRE) Competitors $2.09 -0.11 (-5.00%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$2.10 +0.01 (+0.48%) As of 03/28/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APRE vs. OKYO, VRCA, OTLK, ATNM, RPTX, IBIO, NBRV, KZR, SPRO, and CELUShould you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include OKYO Pharma (OKYO), Verrica Pharmaceuticals (VRCA), Outlook Therapeutics (OTLK), Actinium Pharmaceuticals (ATNM), Repare Therapeutics (RPTX), iBio (IBIO), Nabriva Therapeutics (NBRV), Kezar Life Sciences (KZR), Spero Therapeutics (SPRO), and Celularity (CELU). These companies are all part of the "pharmaceutical products" industry. Aprea Therapeutics vs. OKYO Pharma Verrica Pharmaceuticals Outlook Therapeutics Actinium Pharmaceuticals Repare Therapeutics iBio Nabriva Therapeutics Kezar Life Sciences Spero Therapeutics Celularity Aprea Therapeutics (NASDAQ:APRE) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk, community ranking and dividends. Does the media refer more to APRE or OKYO? In the previous week, Aprea Therapeutics had 15 more articles in the media than OKYO Pharma. MarketBeat recorded 17 mentions for Aprea Therapeutics and 2 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 1.44 beat Aprea Therapeutics' score of 0.55 indicating that OKYO Pharma is being referred to more favorably in the news media. Company Overall Sentiment Aprea Therapeutics Positive OKYO Pharma Positive Is APRE or OKYO more profitable? OKYO Pharma has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,029.50%. OKYO Pharma's return on equity of 0.00% beat Aprea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aprea Therapeutics-1,029.50% -57.86% -47.94% OKYO Pharma N/A N/A N/A Which has more volatility and risk, APRE or OKYO? Aprea Therapeutics has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.34, meaning that its share price is 134% less volatile than the S&P 500. Do analysts rate APRE or OKYO? Aprea Therapeutics presently has a consensus price target of $15.50, suggesting a potential upside of 641.63%. OKYO Pharma has a consensus price target of $7.00, suggesting a potential upside of 418.52%. Given Aprea Therapeutics' higher probable upside, equities research analysts clearly believe Aprea Therapeutics is more favorable than OKYO Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in APRE or OKYO? Aprea Therapeutics received 46 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 57.14% of users gave Aprea Therapeutics an outperform vote. CompanyUnderperformOutperformAprea TherapeuticsOutperform Votes5657.14% Underperform Votes4242.86% OKYO PharmaOutperform Votes10100.00% Underperform VotesNo Votes Do insiders & institutionals have more ownership in APRE or OKYO? 34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 12.8% of Aprea Therapeutics shares are held by company insiders. Comparatively, 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better earnings and valuation, APRE or OKYO? Aprea Therapeutics has higher revenue and earnings than OKYO Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAprea Therapeutics$580K19.79-$14.29M-$2.38-0.88OKYO PharmaN/AN/A-$16.83MN/AN/A SummaryAprea Therapeutics beats OKYO Pharma on 8 of the 14 factors compared between the two stocks. Remove Ads Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRE vs. The Competition Export to ExcelMetricAprea TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.48M$6.91B$5.63B$7.83BDividend YieldN/A2.79%5.33%4.00%P/E Ratio-0.747.2623.6218.74Price / Sales19.79218.91384.7290.81Price / CashN/A65.6738.1734.64Price / Book0.466.386.894.23Net Income-$14.29M$142.34M$3.20B$247.47M7 Day Performance-7.52%-5.83%-3.57%-3.56%1 Month Performance-17.39%-7.55%1.50%-5.81%1 Year Performance-68.76%-11.06%9.32%-0.96% Aprea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APREAprea Therapeutics2.8562 of 5 stars$2.09-5.0%$15.50+641.6%-68.8%$11.48M$580,000.00-0.747Earnings ReportShort Interest ↑Analyst RevisionGap UpOKYOOKYO Pharma3.2125 of 5 stars$1.42+5.2%$7.00+393.0%-9.4%$48.05MN/A0.007Short Interest ↓Positive NewsGap UpVRCAVerrica Pharmaceuticals4.1553 of 5 stars$0.52-6.4%$9.50+1,719.6%-92.7%$47.92M$7.57M-0.2940OTLKOutlook Therapeutics1.5484 of 5 stars$1.50-1.0%$10.20+582.3%-88.9%$47.87MN/A-0.2020ATNMActinium Pharmaceuticals1.7778 of 5 stars$1.49-3.9%$7.40+396.6%N/A$46.48M$81,000.00-1.0730Analyst RevisionNews CoverageGap UpRPTXRepare Therapeutics3.3921 of 5 stars$1.08-3.6%$4.50+316.7%-77.7%$45.91M$53.48M-0.54180Positive NewsIBIOiBio0.5635 of 5 stars$4.63flat$4.30-7.1%+1.5%$45.72M$375,000.000.00100Positive NewsGap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070KZRKezar Life Sciences4.114 of 5 stars$6.16+4.6%$39.50+541.2%-45.4%$44.94M$7M-0.4760Earnings ReportShort Interest ↑Analyst RevisionSPROSpero Therapeutics4.3062 of 5 stars$0.82-0.6%$5.00+511.6%-55.2%$44.57M$89.87M11.68150Earnings ReportHigh Trading VolumeCELUCelularity0.3193 of 5 stars$1.87+2.7%N/A-66.1%$44.52M$48.20M0.00220Short Interest ↑ Remove Ads Related Companies and Tools Related Companies OKYO Competitors VRCA Competitors OTLK Competitors ATNM Competitors RPTX Competitors IBIO Competitors NBRV Competitors KZR Competitors SPRO Competitors CELU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APRE) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APRE Stock Free APRE Stock Alerts